<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39337530</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Emerging Targets in Non-Small Cell Lung Cancer.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10046</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms251810046</ELocationID><Abstract><AbstractText>Lung cancer is responsible for a high burden of disease globally. Over the last two decades, the discovery of targetable oncogenic genomic alterations has revolutionized the treatment landscape for early-stage and advanced non-small cell lung cancer (NSCLC). New molecular drivers continue to emerge as promising therapeutic targets, including KRAS non-G12C, RAF/MEK, HER3, Nectin-4, folate receptor alpha, ITGB6, and PRMT5. In this review, we summarize the emerging molecular targets with a potential clinical impact in advanced NSCLC, elaborating on their clinical characteristics and specific mechanisms and molecular pathways for which targeted treatments are currently available. Additionally, we present an aggregate of ongoing clinical trials investigating the available treatment options targeting such alterations, in addition to their current recruitment status and preliminary efficacy data. These advancements may guide further research endeavors and inform future treatment strategies to improve the management of and transform outcomes for patients with advanced NSCLC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Louisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Samuel-Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soler</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3751-2440</Identifier><AffiliationInfo><Affiliation>Riverside School of Medicine, University of California, Riverside, CA 92521, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reckamp</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0002-9213-0325</Identifier><AffiliationInfo><Affiliation>Samuel-Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sankar</LastName><ForeName>Kamya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Samuel-Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">non-small cell lung cancer</Keyword><Keyword MajorTopicYN="N">novel combinatorial approaches</Keyword><Keyword MajorTopicYN="N">oncogene driver</Keyword><Keyword MajorTopicYN="N">targeted therapies</Keyword></KeywordList><CoiStatement>L.L. and J.S. have no conflicts of interest to disclose. K.S.: Research funding to institution: Genentech; Black Diamond; Lilly; Harpoon Therapeutics; Merck. K.R.: Consultant with honoraria to self: Amgen; AstraZeneca; Blueprint; Daiichi Sankyo; Genentech; GlaxoSmithKline; Janssen; Lilly; Mirati; Novartis; Novocure. Research funding to institution: Genentech; Blueprint; Daiichi Sankyo; Elevation Oncology; Janssen.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39337530</ArticleId><ArticleId IdType="pmc">PMC11432526</ArticleId><ArticleId IdType="doi">10.3390/ijms251810046</ArticleId><ArticleId IdType="pii">ijms251810046</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ettinger D.S., Wood D.E., Aisner D.L., Akerley W., Bauman J.R., Bharat A., Bruno D.S., Chang J.Y., Chirieac L.R., D&#x2019;Amico T.A., et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2022;20:497&#x2013;530. doi: 10.6004/jnccn.2022.0025.</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2022.0025</ArticleId><ArticleId IdType="pubmed">35545176</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed U., Manochakian R., Zhao Y., Lou Y. Targeted therapy in advanced non-small cell lung cancer: Current advances and future trends. J. Hematol. Oncol. 2021;14:108. doi: 10.1186/s13045-021-01121-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-021-01121-2</ArticleId><ArticleId IdType="pmc">PMC8264982</ArticleId><ArticleId IdType="pubmed">34238332</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmedo M.E., Cervera R., Cabezon-Gutierrez L., Lage Y., Corral de la Fuente E., G&#xf3;mez Rueda A., Mielgo-Rubio X., Trujillo J.C., Cou&#xf1;ago F. New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2. World J. Clin. Oncol. 2022;13:276&#x2013;286. doi: 10.5306/wjco.v13.i4.276.</Citation><ArticleIdList><ArticleId IdType="doi">10.5306/wjco.v13.i4.276</ArticleId><ArticleId IdType="pmc">PMC9052069</ArticleId><ArticleId IdType="pubmed">35582653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong D.S., Fakih M.G., Strickler J.H., Desai J., Durm G.A., Shapiro G.I., Falchook G.S., Price T.J., Sacher A., Denlinger C.S., et al. KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors. N. Engl. J. Med. 2020;383:1207&#x2013;1217. doi: 10.1056/NEJMoa1917239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1917239</ArticleId><ArticleId IdType="pmc">PMC7571518</ArticleId><ArticleId IdType="pubmed">32955176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong D.S., DuBois S.G., Kummar S., Farago A.F., Albert C.M., Rohrberg K.S., van Tilburg C.M., Nagasubramanian R., Berlin J.D., Federman N., et al. Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21:531&#x2013;540. doi: 10.1016/S1470-2045(19)30856-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(19)30856-3</ArticleId><ArticleId IdType="pmc">PMC7497841</ArticleId><ArticleId IdType="pubmed">32105622</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y., Yang Y., Li H., Fan Y. Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges. Cancer Treat. Rev. 2023;114:102520. doi: 10.1016/j.ctrv.2023.102520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2023.102520</ArticleId><ArticleId IdType="pubmed">36738637</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebuzzi S.E., Zullo L., Rossi G., Grassi M., Murianni V., Tagliamento M., Prelaj A., Coco S., Longo L., Dal Bello M.G., et al. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Int. J. Mol. Sci. 2021;22:2625. doi: 10.3390/ijms22052625.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052625</ArticleId><ArticleId IdType="pmc">PMC7961376</ArticleId><ArticleId IdType="pubmed">33807876</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox A.D., Der C.J., Philips M.R. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? Clin. Cancer Res. 2015;21:1819&#x2013;1827. doi: 10.1158/1078-0432.CCR-14-3214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-3214</ArticleId><ArticleId IdType="pmc">PMC4400837</ArticleId><ArticleId IdType="pubmed">25878363</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A., Faller D.V. Targeting the RAS oncogene. Expert Opin. Ther. Targets. 2013;17:507&#x2013;531. doi: 10.1517/14728222.2013.764990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.2013.764990</ArticleId><ArticleId IdType="pmc">PMC3804031</ArticleId><ArticleId IdType="pubmed">23360111</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitin N., Rossman K.L., Der C.J. Signaling interplay in Ras superfamily function. Curr. Biol. 2005;15:R563&#x2013;R574. doi: 10.1016/j.cub.2005.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2005.07.010</ArticleId><ArticleId IdType="pubmed">16051167</ArticleId></ArticleIdList></Reference><Reference><Citation>Rom&#xe1;n M., Baraibar I., L&#xf3;pez I., Nadal E., Rolfo C., Vicent S., Gil-Bazo I. KRAS oncogene in non-small cell lung cancer: Clinical perspectives on the treatment of an old target. Mol. Cancer. 2018;17:33. doi: 10.1186/s12943-018-0789-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-018-0789-x</ArticleId><ArticleId IdType="pmc">PMC5817724</ArticleId><ArticleId IdType="pubmed">29455666</ArticleId></ArticleIdList></Reference><Reference><Citation>Reita D., Pabst L., Pencreach E., Gu&#xe9;rin E., Dano L., Rimelen V., Voegeli A.C., Vallat L., Mascaux C., Beau-Faller M. Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance. Cancers. 2022;14:1321. doi: 10.3390/cancers14051321.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14051321</ArticleId><ArticleId IdType="pmc">PMC8909472</ArticleId><ArticleId IdType="pubmed">35267628</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao W., Overman M.J., Boutin A.T., Shang X., Zhao D., Dey P., Li J., Wang G., Lan Z., Tang M., et al. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019;35:559&#x2013;572.e557. doi: 10.1016/j.ccell.2019.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2019.02.008</ArticleId><ArticleId IdType="pmc">PMC6467776</ArticleId><ArticleId IdType="pubmed">30905761</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox A.D., Fesik S.W., Kimmelman A.C., Luo J., Der C.J. Drugging the undruggable RAS: Mission possible? Nat. Rev. Drug Discov. 2014;13:828&#x2013;851. doi: 10.1038/nrd4389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4389</ArticleId><ArticleId IdType="pmc">PMC4355017</ArticleId><ArticleId IdType="pubmed">25323927</ArticleId></ArticleIdList></Reference><Reference><Citation>Singhal A., Li B.T., O&#x2019;Reilly E.M. Targeting KRAS in cancer. Nat. Med. 2024;30:969&#x2013;983. doi: 10.1038/s41591-024-02903-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-02903-0</ArticleId><ArticleId IdType="pmc">PMC11845254</ArticleId><ArticleId IdType="pubmed">38637634</ArticleId></ArticleIdList></Reference><Reference><Citation>Judd J., Abdel Karim N., Khan H., Naqash A.R., Baca Y., Xiu J., VanderWalde A.M., Mamdani H., Raez L.E., Nagasaka M., et al. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Mol. Cancer Ther. 2021;20:2577&#x2013;2584. doi: 10.1158/1535-7163.MCT-21-0201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-21-0201</ArticleId><ArticleId IdType="pmc">PMC9662933</ArticleId><ArticleId IdType="pubmed">34518295</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassar A., Adib E., Kwiatkowski D. Distribution of KRAS G12C Somatic Mutations across Race, Sex, and Cancer Type. N. Engl. J. Med. 2021;384:185&#x2013;187. doi: 10.1056/NEJMc2030638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2030638</ArticleId><ArticleId IdType="pubmed">33497555</ArticleId></ArticleIdList></Reference><Reference><Citation>Salgia R., Pharaon R., Mambetsariev I., Nam A., Sattler M. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) Cell Rep. Med. 2021;2:100186. doi: 10.1016/j.xcrm.2020.100186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2020.100186</ArticleId><ArticleId IdType="pmc">PMC7817862</ArticleId><ArticleId IdType="pubmed">33521700</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrem J.M., Peters U., Sos M.L., Wells J.A., Shokat K.M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548&#x2013;551. doi: 10.1038/nature12796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12796</ArticleId><ArticleId IdType="pmc">PMC4274051</ArticleId><ArticleId IdType="pubmed">24256730</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong D., Yaeger R., Kuboki Y., Masuishi T., Barve M., Falchook S., Govindan R. A phase 1b study of sotorasib, a specific and irreversible KRAS G12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101) J. Clin. Oncol. 2022;40:TPS214. doi: 10.1200/JCO.2022.40.4_suppl.TPS214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2022.40.4_suppl.TPS214</ArticleId></ArticleIdList></Reference><Reference><Citation>de Langen A.J., Johnson M.L., Mazieres J., Dingemans A.C., Mountzios G., Pless M., Wolf J., Schuler M., Lena H., Skoulidis F., et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS. Lancet. 2023;401:733&#x2013;746. doi: 10.1016/S0140-6736(23)00221-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00221-0</ArticleId><ArticleId IdType="pubmed">36764316</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou S.I., J&#xe4;nne P.A., Leal T.A., Rybkin I.I., Sabari J.K., Barve M.A., Bazhenova L., Johnson M.L., Velastegui K.L., Cilliers C., et al. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients with Advanced KRAS G12C Solid Tumors (KRYSTAL-1) J. Clin. Oncol. 2022;40:2530&#x2013;2538. doi: 10.1200/JCO.21.02752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.02752</ArticleId><ArticleId IdType="pmc">PMC9362872</ArticleId><ArticleId IdType="pubmed">35167329</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok T., Yao W., Duruisseaux M., Doucet L., Martinez A., Gregorc V., Juan-Vidal O., Lu S., De Bondt C., De Marinis F. KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation. J. Clin. Oncol. 2024;42:LBA8509. doi: 10.1200/JCO.2024.42.17_suppl.LBA8509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2024.42.17_suppl.LBA8509</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Zheng Q., Kang D., Sun X., Zhu S., Wang Y., Long W., Lin Y. Investigation of KRAS G12C inhibitor JAB-21822 as a single agent and in combination with SHP2 inhibitor JAB-3312 in preclinical cancer models. Ann. Oncol. 2022;33:S1441. doi: 10.1016/j.annonc.2022.10.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2022.10.040</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Fang J., Xing L., Yao Y., Zhang J., Liu L., Wang Y., Hu C., Xiong J., Liu Z., et al. A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation. J. Clin. Oncol. 2024;42:468214. doi: 10.1200/JCO.2024.42.36_suppl.468214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2024.42.36_suppl.468214</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazel D., Nagasaka M. Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. Target. Oncol. 2024;19:297&#x2013;301. doi: 10.1007/s11523-024-01055-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11523-024-01055-y</ArticleId><ArticleId IdType="pmc">PMC11111488</ArticleId><ArticleId IdType="pubmed">38739329</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacher A., LoRusso P., Patel M.R., Miller W.H., Garralda E., Forster M.D., Santoro A., Falcon A., Kim T.W., Paz-Ares L., et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N. Engl. J. Med. 2023;389:710&#x2013;721. doi: 10.1056/NEJMoa2303810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2303810</ArticleId><ArticleId IdType="pubmed">37611121</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng S., Si C., Zhang Y., Van Horn R., Lin X., Gong X., Huber L., Donoho G., Curtis C., Strelow J., et al. Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor. Cancer Res. 2021;81:1259. doi: 10.1158/1538-7445.AM2021-1259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2021-1259</ArticleId></ArticleIdList></Reference><Reference><Citation>Murciano-Goroff Y., Heist R., Kuboki Y., Koyama T., Ammakkanavar N., Hollebecque A., Patnaik A., Shimizu T., Spira A. CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors. Cancer Res. 2023;83:CT028. doi: 10.1158/1538-7445.AM2023-CT028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2023-CT028</ArticleId></ArticleIdList></Reference><Reference><Citation>Negrao M., Arbour K., Burns T., Cappuzzo F., Dingemans A., Girard N., Gronberg B., Hochmair M., Leal T., Lindsay C.R., et al. SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC. J. Clin. Oncol. 2024;42:TPS8649. doi: 10.1200/JCO.2024.42.16_suppl.TPS8649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2024.42.16_suppl.TPS8649</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss A., Lorthiois E., Barys L., Beyer K.S., Bomio-Confaglia C., Burks H., Chen X., Cui X., de Kanter R., Dharmarajan L., et al. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022;12:1500&#x2013;1517. doi: 10.1158/2159-8290.CD-22-0158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-22-0158</ArticleId><ArticleId IdType="pmc">PMC9394399</ArticleId><ArticleId IdType="pubmed">35404998</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassier P., Dooms C., Gazzah A., Felip E., Steeghs N., Rohrberg K., De Braud F., Solomon B., Schuler M. KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C -mutated solid tumors including non-small cell lung cancer (NSCLC) J. Clin. Oncol. 2023;41:9007. doi: 10.1200/JCO.2023.41.16_suppl.9007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2023.41.16_suppl.9007</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappuzzo F., Castro G., Kang J., Wu Y., Brustugun O., Cheema P., Owonikoko T., Longin A., Boran A. KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC. J. Clin. Oncol. 2023;41:TPS9144. doi: 10.1200/JCO.2023.41.16_suppl.TPS9144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2023.41.16_suppl.TPS9144</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z., Weng J., Niu H., Yang H., Liu R., Weng Y., Zhu Q., Zhang Y., Tao L., Wang Z., et al. D-1553: A novel KRAS G12C inhibitor with potent and selective cellular and in vivo antitumor activity. Cancer Sci. 2023;114:2951&#x2013;2960. doi: 10.1111/cas.15829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.15829</ArticleId><ArticleId IdType="pmc">PMC10323112</ArticleId><ArticleId IdType="pubmed">37158138</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Song Z., Zhao Y., Wang P., Jiang L., Gong Y., Zhou J., Jian H., Dong X., Zhuang W., et al. D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS. J. Thorac. Oncol. 2023;18:940&#x2013;951. doi: 10.1016/j.jtho.2023.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2023.03.015</ArticleId><ArticleId IdType="pubmed">36948246</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahadevan K.K., McAndrews K.M., LeBleu V.S., Yang S., Lyu H., Li B., Sockwell A.M., Kirtley M.L., Morse S.J., Moreno Diaz B.A., et al. Oncogenic Kras G12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8+ T cells dependent manner. bioRxiv. 2023 doi: 10.1101/2023.02.15.528757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.02.15.528757</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C., Song Z., Zhang Y., Huang D., Yang Z., Zhou M. LBA33 a first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation. Ann. Oncol. 2023;34:S1273. doi: 10.1016/j.annonc.2023.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2023.10.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L., Menard M., Weller C., Wang Z., Burnett L., Aronchik I., Steele S., Flagella M., Zhao R., Evans J. Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers. Cancer Res. 2023;83:526. doi: 10.1158/1538-7445.AM2023-526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2023-526</ArticleId></ArticleIdList></Reference><Reference><Citation>Farren M., Roman V., Gallion A., Allali-Hassani A., Sokolsky A., Kong W., Smith A., Wang H., Correa G. Abstract 5900: INCB161734: A Novel, Potent, and Orally Bioavailable KRAS G12D Selective Inhibitor Demonstrates Antitumor Activity in KRAS G12D Mutant Tumors. Cancer Res. 2024;84:5900. doi: 10.1158/1538-7445.AM2024-5900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2024-5900</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H.Y., Xin M., Zhang S.Q. Progress of small molecules for targeted protein degradation: PROTACs and other technologies. Drug Dev. Res. 2023;84:337&#x2013;394. doi: 10.1002/ddr.22026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ddr.22026</ArticleId><ArticleId IdType="pubmed">36606428</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagashima T., Yoshinari T., Nishizono Y., Tasaki M., Inamura K., Ishioka H., Suzuki A., Osaki F., Yamanaka Y., Hayakawa M. Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models. Cancer Res. 2023;83:5735. doi: 10.1158/1538-7445.AM2023-5735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2023-5735</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolcher A., Park W., Wang J., Spira A., Janne P., Lee H., Gill S., LoRusso P., Herzberg B. Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations. J. Clin. Oncol. 2023;41:TPS764. doi: 10.1200/JCO.2023.41.4_suppl.TPS764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2023.41.4_suppl.TPS764</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson W., Wildes D., Rice M., Lee B., Jiang J., Wang Z., Chang S., Flagella M., Mu Y. Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RAS MULTI (ON) inhibitor. J. Clin. Oncol. 2022;40:591. doi: 10.1200/JCO.2022.40.4_suppl.591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2022.40.4_suppl.591</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbour K., Punekar S., Garrido-Laguna I., Hong D., Wolpin B., Pelster M., Barve M., Starodub A., Sommerhalder D. Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) Ann. Oncol. 2023;34:S458. doi: 10.1016/j.annonc.2023.09.1838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2023.09.1838</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolani B., Celli A., Yao Y., Tan Y.Z., Fetter R., Liem C.R., de Smith A.J., Vasanthakumar T., Bisignano P., Cotton A.D., et al. Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice. Nat. Biotechnol. 2022;40:1834&#x2013;1844. doi: 10.1038/s41587-022-01386-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-022-01386-z</ArticleId><ArticleId IdType="pmc">PMC9750872</ArticleId><ArticleId IdType="pubmed">35879364</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Rominger D., Vo E., Silva J., Zhang Y., Lee G., Micozzi J., Reid B., McDonough B., Hospital A. Discovery and characterization of QTX3034, a potent, selective, and orally bioavailable allosteric KRAS inhibitor. Cancer Res. 2023;83:LB320. doi: 10.1158/1538-7445.AM2023-LB320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2023-LB320</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Weaver D., Drakas R., Lou Y. The small molecule KRAS inhibitor, TEB-17231, blocks tumor progression and overcomes KRASG12C inhibitor mediated resistance. Cancer Res. 2023;83:2627. doi: 10.1158/1538-7445.AM2023-2627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2023-2627</ArticleId></ArticleIdList></Reference><Reference><Citation>Patnaik A., Pelster M., Hong D., Strickler J., Garrido-Laguna I., Aguirre A., Curran D., Woo T., Spira A. A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRAS G12D mutation. J. Clin. Oncol. 2024;42:TPS3172. doi: 10.1200/JCO.2024.42.16_suppl.TPS3172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2024.42.16_suppl.TPS3172</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsen H., Norseth H., Remen N., Abrahamsen I., Lys&#xe9;n A., Schjesvold F. PB2118: TG01-STUDY: A Phase 1/2 Study with Tg01 Immunotherapy Vaccination in Patients with Confirmed Nras/Kras Mutation on Codon 12/13 and Multiple Myeloma or High-Risk Smoldering Myeloma. HemaSphere. 2023;7:e51467aa. doi: 10.1097/01.HS9.0000975244.51467.aa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.HS9.0000975244.51467.aa</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer D.H., Valle J.W., Ma Y.T., Faluyi O., Neoptolemos J.P., Jensen Gjertsen T., Iversen B., Amund Eriksen J., M&#xf8;ller A.S., Aksnes A.K., et al. TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): A single-arm, phase 1/2 trial. Br. J. Cancer. 2020;122:971&#x2013;977. doi: 10.1038/s41416-020-0752-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-020-0752-7</ArticleId><ArticleId IdType="pmc">PMC7109101</ArticleId><ArticleId IdType="pubmed">32063605</ArticleId></ArticleIdList></Reference><Reference><Citation>Haldar S., Heumann T., Berg M., Ferguson A., Lim S., Wang H., Nauroth J., Lahertu D., Jaffee E., Azad N., et al. A phase I study of a mutant KRAS-targeted long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer and MMR-proficient metastatic colorectal cancer. J. Clin. Oncol. 2023;41:TPS814. doi: 10.1200/JCO.2023.41.4_suppl.TPS814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2023.41.4_suppl.TPS814</ArticleId></ArticleIdList></Reference><Reference><Citation>Seenappa L.M., Jakubowski A., Steinbuck M.P., Palmer E., Haqq C.M., Carter C., Fontenot J., Villinger F., McNeil L.K., DeMuth P.C. Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates. NPJ Vaccines. 2022;7:128. doi: 10.1038/s41541-022-00560-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00560-3</ArticleId><ArticleId IdType="pmc">PMC9616425</ArticleId><ArticleId IdType="pubmed">36307453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L., Hostetler A., Morgan D.M., Maiorino L., Sulkaj I., Whittaker C.A., Neeser A., Pires I.S., Yousefpour P., Gregory J., et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186:3148&#x2013;3165.e3120. doi: 10.1016/j.cell.2023.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.06.002</ArticleId><ArticleId IdType="pmc">PMC10372881</ArticleId><ArticleId IdType="pubmed">37413990</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly E., Wainberg Z., Weekes C., Furqan M., Kasi P., Devoe C., Leal A., Chung V., Perry J. AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer. J. Clin. Oncol. 2023;41:2528. doi: 10.1200/JCO.2023.41.16_suppl.2528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2023.41.16_suppl.2528</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Wang W., Zou S., Xu Z., Cao D., Zhang S., Wei M., Zhan Q., Wen C., Li F., et al. Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: Clinical benefit in patients with advanced solid tumors. Cell Res. 2024;34:661&#x2013;664. doi: 10.1038/s41422-024-00990-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-024-00990-9</ArticleId><ArticleId IdType="pmc">PMC11369195</ArticleId><ArticleId IdType="pubmed">38914844</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo M., Wetterwald L., Friedlaender A., Parikh K., Addeo A. Cellular Therapy in NSCLC: Between Myth and Reality. Curr. Oncol. Rep. 2023;25:1161&#x2013;1174. doi: 10.1007/s11912-023-01443-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11912-023-01443-z</ArticleId><ArticleId IdType="pmc">PMC10556121</ArticleId><ArticleId IdType="pubmed">37646900</ArticleId></ArticleIdList></Reference><Reference><Citation>Katiyar V., Chesney J., Kloecker G. Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy. Cancers. 2023;15:3733. doi: 10.3390/cancers15143733.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15143733</ArticleId><ArticleId IdType="pmc">PMC10377757</ArticleId><ArticleId IdType="pubmed">37509394</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E., Niessen R.C., Oliveira C., Alhopuro P., Moutinho C., Esp&#xed;n E., Armengol M., Sijmons R.H., Kleibeuker J.H., Seruca R., et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene. 2005;24:3995&#x2013;3998. doi: 10.1038/sj.onc.1208569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208569</ArticleId><ArticleId IdType="pubmed">15782118</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949&#x2013;954. doi: 10.1038/nature00766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature00766</ArticleId><ArticleId IdType="pubmed">12068308</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardarella S., Ogino A., Nishino M., Butaney M., Shen J., Lydon C., Yeap B.Y., Sholl L.M., Johnson B.E., J&#xe4;nne P.A. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin. Cancer Res. 2013;19:4532&#x2013;4540. doi: 10.1158/1078-0432.CCR-13-0657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0657</ArticleId><ArticleId IdType="pmc">PMC3762878</ArticleId><ArticleId IdType="pubmed">23833300</ArticleId></ArticleIdList></Reference><Reference><Citation>Planchard D., Sanborn R.E., Negrao M.V., Vaishnavi A., Smit E.F. BRAF V600E-mutant metastatic NSCLC: Disease overview and treatment landscape. NPJ Precis. Oncol. 2024;8:90. doi: 10.1038/s41698-024-00552-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41698-024-00552-7</ArticleId><ArticleId IdType="pmc">PMC11021522</ArticleId><ArticleId IdType="pubmed">38627602</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetti A., Felicioni L., Malatesta S., Grazia Sciarrotta M., Guetti L., Chella A., Viola P., Pullara C., Mucilli F., Buttitta F. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J. Clin. Oncol. 2011;29:3574&#x2013;3579. doi: 10.1200/JCO.2011.35.9638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.35.9638</ArticleId><ArticleId IdType="pubmed">21825258</ArticleId></ArticleIdList></Reference><Reference><Citation>Negrao M.V., Skoulidis F., Montesion M., Schulze K., Bara I., Shen V., Xu H., Hu S., Sui D., Elamin Y.Y., et al. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J. Immunother. Cancer. 2021;9:e002891. doi: 10.1136/jitc-2021-002891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-002891</ArticleId><ArticleId IdType="pmc">PMC8356172</ArticleId><ArticleId IdType="pubmed">34376553</ArticleId></ArticleIdList></Reference><Reference><Citation>Long G.V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., Garbe C., Jouary T., Hauschild A., Grob J.J., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 2014;371:1877&#x2013;1888. doi: 10.1056/NEJMoa1406037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1406037</ArticleId><ArticleId IdType="pubmed">25265492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascierto P.A., Dr&#xe9;no B., Larkin J., Ribas A., Liszkay G., Maio M., Mandal&#xe0; M., Demidov L., Stroyakovskiy D., Thomas L., et al. 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clin. Cancer Res. 2021;27:5225&#x2013;5235. doi: 10.1158/1078-0432.CCR-21-0809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-21-0809</ArticleId><ArticleId IdType="pmc">PMC9401485</ArticleId><ArticleId IdType="pubmed">34158360</ArticleId></ArticleIdList></Reference><Reference><Citation>Dummer R., Flaherty K.T., Robert C., Arance A., de Groot J.W.B., Garbe C., Gogas H.J., Gutzmer R., Krajsov&#xe1; I., Liszkay G., et al. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients with BRAF V600&#x2013;Mutant Melanoma. J. Clin. Oncol. 2022;40:4178&#x2013;4188. doi: 10.1200/JCO.21.02659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.02659</ArticleId><ArticleId IdType="pmc">PMC9916040</ArticleId><ArticleId IdType="pubmed">35862871</ArticleId></ArticleIdList></Reference><Reference><Citation>Planchard D., Besse B., Groen H.J.M., Hashemi S.M.S., Mazieres J., Kim T.M., Quoix E., Souquet P.J., Barlesi F., Baik C., et al. Phase 2 Study of Dabrafenib Plus Trametinib in Patients with BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. J. Thorac. Oncol. 2022;17:103&#x2013;115. doi: 10.1016/j.jtho.2021.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2021.08.011</ArticleId><ArticleId IdType="pubmed">34455067</ArticleId></ArticleIdList></Reference><Reference><Citation>Riely G.J., Smit E.F., Ahn M.J., Felip E., Ramalingam S.S., Tsao A., Johnson M., Gelsomino F., Esper R., Nadal E., et al. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients with BRAFV600-Mutant Metastatic Non&#x2013;Small-Cell Lung Cancer. J. Clin. Oncol. 2023;41:3700&#x2013;3711. doi: 10.1200/JCO.23.00774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.23.00774</ArticleId><ArticleId IdType="pubmed">37270692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman D.M., Puzanov I., Subbiah V., Faris J.E., Chau I., Blay J.Y., Wolf J., Raje N.S., Diamond E.L., Hollebecque A., et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N. Engl. J. Med. 2015;373:726&#x2013;736. doi: 10.1056/NEJMoa1502309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1502309</ArticleId><ArticleId IdType="pmc">PMC4971773</ArticleId><ArticleId IdType="pubmed">26287849</ArticleId></ArticleIdList></Reference><Reference><Citation>Meric-Bernstam F., Rothe M., Mangat P.K., Garrett-Mayer E., Gutierrez R., Ahn E.R., Cannon T.L., Powell S., Krauss J.C., Reynolds C.M., et al. Cobimetinib Plus Vemurafenib in Patients with Solid Tumors with BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry Study. JCO Precis. Oncol. 2023;7:e2300385. doi: 10.1200/PO.23.00385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/PO.23.00385</ArticleId><ArticleId IdType="pmc">PMC10735080</ArticleId><ArticleId IdType="pubmed">38096472</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautschi O., Milia J., Cabarrou B., Bluthgen M.V., Besse B., Smit E.F., Wolf J., Peters S., Fr&#xfc;h M., Koeberle D., et al. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J. Thorac. Oncol. 2015;10:1451&#x2013;1457. doi: 10.1097/JTO.0000000000000625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JTO.0000000000000625</ArticleId><ArticleId IdType="pubmed">26200454</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz-Cuaran S., Mezquita L., Swalduz A., Aldea M., Mazieres J., Leonce C., Jovelet C., Pradines A., Avrillon V., Chumbi Flores W.R., et al. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF -Mutant Metastatic Non-Small Cell Lung Cancer. Clin. Cancer Res. 2020;26:6242&#x2013;6253. doi: 10.1158/1078-0432.CCR-20-1037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-20-1037</ArticleId><ArticleId IdType="pubmed">32859654</ArticleId></ArticleIdList></Reference><Reference><Citation>Karoulia Z., Wu Y., Ahmed T.A., Xin Q., Bollard J., Krepler C., Wu X., Zhang C., Bollag G., Herlyn M., et al. An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell. 2016;30:485&#x2013;498. doi: 10.1016/j.ccell.2016.06.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2016.06.024</ArticleId><ArticleId IdType="pmc">PMC5021590</ArticleId><ArticleId IdType="pubmed">27523909</ArticleId></ArticleIdList></Reference><Reference><Citation>Okaniwa M., Hirose M., Arita T., Yabuki M., Nakamura A., Takagi T., Kawamoto T., Uchiyama N., Sumita A., Tsutsumi S., et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: Design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J. Med. Chem. 2013;56:6478&#x2013;6494. doi: 10.1021/jm400778d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm400778d</ArticleId><ArticleId IdType="pubmed">23906342</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenschein G.R., Saintigny P., Liu S., Kim E.S., Tsao A.S., Herbst R.S., Alden C., Lee J.J., Tang X., Stewart D.J., et al. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin. Cancer Res. 2013;19:6967&#x2013;6975. doi: 10.1158/1078-0432.CCR-12-1818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-12-1818</ArticleId><ArticleId IdType="pmc">PMC3905243</ArticleId><ArticleId IdType="pubmed">24166906</ArticleId></ArticleIdList></Reference><Reference><Citation>Paz-Ares L., Hirsh V., Zhang L., de Marinis F., Yang J.C., Wakelee H.A., Seto T., Wu Y.L., Novello S., Juh&#xe1;sz E., et al. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. J. Thorac. Oncol. 2015;10:1745&#x2013;1753. doi: 10.1097/JTO.0000000000000693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JTO.0000000000000693</ArticleId><ArticleId IdType="pubmed">26743856</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W.L., Tang Z.H., Xie T.T., Xiao B.K., Zhang X.Y., Guo D.H., Wang D.X., Pei F., Si H.Y., Zhu M. Efficacy and safety of sorafenib for advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Asian Pac. J. Cancer Prev. 2014;15:5691&#x2013;5696. doi: 10.7314/APJCP.2014.15.14.5691.</Citation><ArticleIdList><ArticleId IdType="doi">10.7314/APJCP.2014.15.14.5691</ArticleId><ArticleId IdType="pubmed">25081687</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S., Lee J., Kim T., Kim J., Kim Y., Hong Y., Kim S. A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion. J. Clin. Oncol. 2021;39:3007. doi: 10.1200/JCO.2021.39.15_suppl.3007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2021.39.15_suppl.3007</ArticleId></ArticleIdList></Reference><Reference><Citation>de Braud F., Dooms C., Heist R.S., Lebbe C., Wermke M., Gazzah A., Schadendorf D., Rutkowski P., Wolf J., Ascierto P.A., et al. Initial Evidence for the Efficacy of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma: Results from the Expansion Arm of a Phase Ib, Open-Label Study. J. Clin. Oncol. 2023;41:2651&#x2013;2660. doi: 10.1200/JCO.22.02018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.22.02018</ArticleId><ArticleId IdType="pubmed">36947734</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira A., Gambardella V., Kato S., Perez C., Mckean M., Cao M., Kim R., Chen C. Abstract CT032: Trials in progress: A global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma. Cancer Res. 2023;83:CT032. doi: 10.1158/1538-7445.AM2023-CT032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2023-CT032</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan R.J., Hollebecque A., Flaherty K.T., Shapiro G.I., Rodon Ahnert J., Millward M.J., Zhang W., Gao L., Sykes A., Willard M.D., et al. A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. Mol. Cancer Ther. 2020;19:460&#x2013;467. doi: 10.1158/1535-7163.MCT-19-0681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-19-0681</ArticleId><ArticleId IdType="pubmed">31645440</ArticleId></ArticleIdList></Reference><Reference><Citation>Piha-Paul S., Nagpal S., Weise A., Braiteh F., Chen C., Huang C., Liu W., Hu Y., Yang Z., Tsai K. A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600-mutated solid tumors. J. Clin. Oncol. 2023;41:3098. doi: 10.1200/JCO.2023.41.16_suppl.3098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2023.41.16_suppl.3098</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J., McKean M., Gadgeel S., Bowles D., Haq R., Yaeger R., Taylor M., Maity A., Drescher S. A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations. J. Clin. Oncol. 2023;41:TPS3164. doi: 10.1200/JCO.2023.41.16_suppl.TPS3164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2023.41.16_suppl.TPS3164</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Han X., Zhao Q., Zheng Y., Chen J., Yu X., Fang J., Liu Y., Huang D., Liu T., et al. Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: An open-label, single-arm, multicenter, phase I study. Exp. Hematol. Oncol. 2024;13:60. doi: 10.1186/s40164-024-00528-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40164-024-00528-0</ArticleId><ArticleId IdType="pmc">PMC11167782</ArticleId><ArticleId IdType="pubmed">38867257</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasco D.W., Medina T., Corrie P., Pavlick A.C., Middleton M.R., Lorigan P., Hebert C., Plummer R., Larkin J., Agarwala S.S., et al. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer Chemother. Pharmacol. 2023;92:15&#x2013;28. doi: 10.1007/s00280-023-04544-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00280-023-04544-5</ArticleId><ArticleId IdType="pmc">PMC10261210</ArticleId><ArticleId IdType="pubmed">37219686</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad M., Zorea J., Jagadeeshan S., Shnerb A.B., Mathukkada S., Bouaoud J., Michon L., Novoplansky O., Badarni M., Cohen L., et al. MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. J. Immunother. Cancer. 2022;10:e003917. doi: 10.1136/jitc-2021-003917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-003917</ArticleId><ArticleId IdType="pmc">PMC8928405</ArticleId><ArticleId IdType="pubmed">35292516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalingam S., Fakih M., Strickler J., Govindan R., Li B., Goldberg S., Gandara D., Burns T., Barve M., Shu C. Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors. Mol. Cancer Ther. 2021;20:P05-01. doi: 10.1158/1535-7163.TARG-21-P05-01.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.TARG-21-P05-01</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuss J., Gandhi S., Spigel D., Janne P., Paz-Ares L., Gadgeel S., Patel J., Passiglia F., Spira A. RAMP 202: A phase 2 study of avutometinib (VS-6766) &#xb1; defactinib, in patients with advanced KRAS G12V mutant non&#x2013;small cell lung cancer (NSCLC) J. Clin. Oncol. 2023;41:9100. doi: 10.1200/JCO.2023.41.16_suppl.9100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2023.41.16_suppl.9100</ArticleId></ArticleIdList></Reference><Reference><Citation>Awad M., Goldschmidt J., Spira A., Malhotra R., Yorio J., Bhambhani V., Cheng Y., Lee P., Govidan R. Abstract C026: Initial safety, pharmacokinetics, and recommended Phase 2 dose from RAMP 203: A Phase 1/2 study of Avutometinib + Sotorasib in KRAS G12C Mutant Non-Small Cell Lung Cancer. Mol. Cancer Ther. 2023;22:C026. doi: 10.1158/1535-7163.TARG-23-C026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.TARG-23-C026</ArticleId></ArticleIdList></Reference><Reference><Citation>Minchom A., Perez V., Morton C., Manickavasagar T., Nintos G., Lai-Kwon J., Guo C., Tunariu N., Parker T. Phase I trial of the RAF/MEK clamp VS-6766 in combination with everolimus using an intermittent schedule with expansion in NSCLC across multiple KRAS variants. J. Clin. Oncol. 2022;40:9018. doi: 10.1200/JCO.2022.40.16_suppl.9018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2022.40.16_suppl.9018</ArticleId></ArticleIdList></Reference><Reference><Citation>Della Corte C.M., Barra G., Ciaramella V., Di Liello R., Vicidomini G., Zappavigna S., Luce A., Abate M., Fiorelli A., Caraglia M., et al. Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures. J. Exp. Clin. Cancer Res. 2019;38:253. doi: 10.1186/s13046-019-1257-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-019-1257-1</ArticleId><ArticleId IdType="pmc">PMC6567578</ArticleId><ArticleId IdType="pubmed">31196138</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.W., Zhang Y., Eoh K.J., Sharma R., Sanmamed M.F., Wu J., Choi J., Park H.S., Iwasaki A., Kaftan E., et al. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. J. Thorac. Oncol. 2019;14:1046&#x2013;1060. doi: 10.1016/j.jtho.2019.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2019.02.004</ArticleId><ArticleId IdType="pmc">PMC6542636</ArticleId><ArticleId IdType="pubmed">30771521</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellmann M.D., Kim T.W., Lee C.B., Goh B.C., Miller W.H., Oh D.Y., Jamal R., Chee C.E., Chow L.Q.M., Gainor J.F., et al. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Ann. Oncol. 2019;30:1134&#x2013;1142. doi: 10.1093/annonc/mdz113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdz113</ArticleId><ArticleId IdType="pmc">PMC6931236</ArticleId><ArticleId IdType="pubmed">30918950</ArticleId></ArticleIdList></Reference><Reference><Citation>Theriau C., Feng J., Eng L., Shepherd F., DeCarolis M., Glenns V., Kulkarni S., VanderMeer R., Zurawska-Fortin U., Hao D. Abstract CT206: A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC) Cancer Res. 2023;83:CT206. doi: 10.1158/1538-7445.AM2023-CT206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2023-CT206</ArticleId></ArticleIdList></Reference><Reference><Citation>Theriau C., Feng J., Eng L., Shepherd F., De Carolis M., Glenns V., Kulkarni S., Vandermeer R., Zurawska-Fortin U., Hao D., et al. A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NCT03991819) Ann. Oncol. 2024;9((Suppl. S3)):1&#x2013;53. doi: 10.1016/j.esmoop.2024.102650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esmoop.2024.102650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci P.F., Di Giacomo A.M., Del Vecchio M., Atkinson V., Schmidt H., Schachter J., Queirolo P., Long G.V., Stephens R., Svane I.M., et al. KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF&#x2014;Mutant melanoma. J. Immunother. Cancer. 2020;8:e001806. doi: 10.1136/jitc-2020-001806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-001806</ArticleId><ArticleId IdType="pmc">PMC7768966</ArticleId><ArticleId IdType="pubmed">33361337</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer L., Livingstone E., Krackhardt A., Schultz E.S., G&#xf6;ppner D., Assaf C., Trebing D., Stelter K., Windemuth-Kieselbach C., Ugurel S., et al. Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: Safety and tolerability results from the phase I IMMU-TARGET trial. Eur. J. Cancer. 2021;158:72&#x2013;84. doi: 10.1016/j.ejca.2021.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2021.09.011</ArticleId><ArticleId IdType="pubmed">34655839</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi F., Telesco S.E., Liu Y., Radhakrishnan R., Lemmon M.A. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. USA. 2010;107:7692&#x2013;7697. doi: 10.1073/pnas.1002753107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1002753107</ArticleId><ArticleId IdType="pmc">PMC2867849</ArticleId><ArticleId IdType="pubmed">20351256</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra R., Patel H., Alanazi S., Yuan L., Garrett J.T. HER3 signaling and targeted therapy in cancer. Oncol. Rev. 2018;12:355. doi: 10.4081/oncol.2018.355.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/oncol.2018.355</ArticleId><ArticleId IdType="pmc">PMC6047885</ArticleId><ArticleId IdType="pubmed">30057690</ArticleId></ArticleIdList></Reference><Reference><Citation>Manickavasagar T., Yuan W., Carreira S., Gurel B., Miranda S., Ferreira A., Crespo M., Riisnaes R., Baker C., O'Brien M., et al. HER3 expression and MEK activation in non-small-cell lung carcinoma. Lung Cancer Manag. 2021;10:LMT48. doi: 10.2217/lmt-2020-0031.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/lmt-2020-0031</ArticleId><ArticleId IdType="pmc">PMC8162178</ArticleId><ArticleId IdType="pubmed">34084213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu H., Han A., Polsdofer E., Liu S., Liu B. Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharm. Sin. B. 2018;8:503&#x2013;510. doi: 10.1016/j.apsb.2018.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2018.05.010</ArticleId><ArticleId IdType="pmc">PMC6090011</ArticleId><ArticleId IdType="pubmed">30109175</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Liu S., Lyu H., Riker A.I., Zhang Y., Liu B. Development of Effective Therapeutics Targeting HER3 for Cancer Treatment. Biol. Proced. Online. 2019;21:5. doi: 10.1186/s12575-019-0093-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12575-019-0093-1</ArticleId><ArticleId IdType="pmc">PMC6425631</ArticleId><ArticleId IdType="pubmed">30930695</ArticleId></ArticleIdList></Reference><Reference><Citation>Baselga J., Swain S.M. Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer. 2009;9:463&#x2013;475. doi: 10.1038/nrc2656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2656</ArticleId><ArticleId IdType="pubmed">19536107</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi E.S., Harclerode D., Gondo M., Stephenson M., Brown R.W., Younes M., Cagle P.T. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod. Pathol. 1997;10:142&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">9127320</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandullo-S&#xe1;nchez L., Oca&#xf1;a A., Pandiella A. HER3 in cancer: From the bench to the bedside. J. Exp. Clin. Cancer Res. 2022;41:310. doi: 10.1186/s13046-022-02515-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-022-02515-x</ArticleId><ArticleId IdType="pmc">PMC9585794</ArticleId><ArticleId IdType="pubmed">36271429</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q., Jia G., Zhang X., Ma W. Targeting HER3 to overcome EGFR TKI resistance in NSCLC. Front. Immunol. 2023;14:1332057. doi: 10.3389/fimmu.2023.1332057.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1332057</ArticleId><ArticleId IdType="pmc">PMC10794487</ArticleId><ArticleId IdType="pubmed">38239350</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi B., Cha M., Eun G.S., Lee D.H., Lee S., Ehsan M., Chae P.S., Heo W.D., Park Y., Yoon T.Y. Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers. Elife. 2020;9:e53934. doi: 10.7554/eLife.53934.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.53934</ArticleId><ArticleId IdType="pmc">PMC7176432</ArticleId><ArticleId IdType="pubmed">32267234</ArticleId></ArticleIdList></Reference><Reference><Citation>Gala K., Chandarlapaty S. Molecular pathways: HER3 targeted therapy. Clin. Cancer Res. 2014;20:1410&#x2013;1416. doi: 10.1158/1078-0432.CCR-13-1549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-13-1549</ArticleId><ArticleId IdType="pmc">PMC3977203</ArticleId><ArticleId IdType="pubmed">24520092</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., Moasser M.M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437&#x2013;441. doi: 10.1038/nature05474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05474</ArticleId><ArticleId IdType="pmc">PMC3025857</ArticleId><ArticleId IdType="pubmed">17206155</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin D.N., Sergina N., Ahuja D., McMahon M., Blair J.A., Wang D., Hann B., Koch K.M., Shokat K.M., Moasser M.M. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci. Transl. Med. 2010;2:16ra17. doi: 10.1126/scitranslmed.3000389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3000389</ArticleId><ArticleId IdType="pmc">PMC3033659</ArticleId><ArticleId IdType="pubmed">20371474</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonesaka K., Hirotani K., Kawakami H., Takeda M., Kaneda H., Sakai K., Okamoto I., Nishio K., J&#xe4;nne P.A., Nakagawa K. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib. Oncogene. 2016;35:878&#x2013;886. doi: 10.1038/onc.2015.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2015.142</ArticleId><ArticleId IdType="pubmed">25961915</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H.A., Goto Y., Hayashi H., Felip E., Chih-Hsin Yang J., Reck M., Yoh K., Lee S.H., Paz-Ares L., Besse B., et al. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J. Clin. Oncol. 2023;41:5363&#x2013;5375. doi: 10.1200/JCO.23.01476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.23.01476</ArticleId><ArticleId IdType="pmc">PMC10713116</ArticleId><ArticleId IdType="pubmed">37689979</ArticleId></ArticleIdList></Reference><Reference><Citation>Cejalvo J.M., Jacob W., Fleitas Kanonnikoff T., Felip E., Navarro Mendivil A., Martinez Garcia M., Taus Garcia A., Leighl N., Lassen U., Mau-Soerensen M., et al. A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open. 2019;4:e000532. doi: 10.1136/esmoopen-2019-000532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/esmoopen-2019-000532</ArticleId><ArticleId IdType="pmc">PMC6678014</ArticleId><ArticleId IdType="pubmed">31423336</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Yao J., Qu C., Luo L., Li B., Zhang Y., Zhu Z., Qiu Y., Hua H. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors. J. Transl. Med. 2024;22:362. doi: 10.1186/s12967-024-05133-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-024-05133-7</ArticleId><ArticleId IdType="pmc">PMC11022355</ArticleId><ArticleId IdType="pubmed">38632563</ArticleId></ArticleIdList></Reference><Reference><Citation>Janne P., Mostillo J., Shrestha P., Zhang R., Fan P., Cantero F. Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC. J. Clin. Oncol. 2022;40:TPS3161. doi: 10.1200/JCO.2022.40.16_suppl.TPS3161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2022.40.16_suppl.TPS3161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Zhang L., Fang W., Yang Y., Huang Y., Zou W., Wang Z., Ding M., Peng Y. SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study. J. Clin. Oncol. 2023;41:9025. doi: 10.1200/JCO.2023.41.16_suppl.9025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2023.41.16_suppl.9025</ArticleId></ArticleIdList></Reference><Reference><Citation>Rikitake Y., Mandai K., Takai Y. The role of nectins in different types of cell-cell adhesion. J. Cell Sci. 2012;125:3713&#x2013;3722. doi: 10.1242/jcs.099572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.099572</ArticleId><ArticleId IdType="pubmed">23027581</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K.L., Buchanan P.C., Manion R.D., Shukla D.M., Braumberger K., Bruggemeyer C., Skubitz A.P. The expression of Nectin-4 on the surface of ovarian cancer cells alters their ability to adhere, migrate, aggregate, and proliferate. Oncotarget. 2017;8:9717&#x2013;9738. doi: 10.18632/oncotarget.14206.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.14206</ArticleId><ArticleId IdType="pmc">PMC5354766</ArticleId><ArticleId IdType="pubmed">28038455</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouleftour W., Guillot A., Magne N. The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review. Mol. Cancer Ther. 2022;21:493&#x2013;501. doi: 10.1158/1535-7163.MCT-21-0846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-21-0846</ArticleId><ArticleId IdType="pubmed">35131876</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethy C., Goutam K., Nayak D., Pradhan R., Molla S., Chatterjee S., Rout N., Wyatt M.D., Narayan S., Kundu C.N. Clinical significance of a pvrl 4 encoded gene Nectin-4 in metastasis and angiogenesis for tumor relapse. J. Cancer Res. Clin. Oncol. 2020;146:245&#x2013;259. doi: 10.1007/s00432-019-03055-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00432-019-03055-2</ArticleId><ArticleId IdType="pmc">PMC11804762</ArticleId><ArticleId IdType="pubmed">31617074</ArticleId></ArticleIdList></Reference><Reference><Citation>Challita-Eid P.M., Satpayev D., Yang P., An Z., Morrison K., Shostak Y., Raitano A., Nadell R., Liu W., Lortie D.R., et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res. 2016;76:3003&#x2013;3013. doi: 10.1158/0008-5472.CAN-15-1313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-15-1313</ArticleId><ArticleId IdType="pubmed">27013195</ArticleId></ArticleIdList></Reference><Reference><Citation>Muro K., Feinstein T., Baranda J., Bonta I., Kitazono S., Gersten T., Gandhi L., Kudo T., Kaplan J. Enfortumab vedotin (EV) in non-squamous and squamous non&#x2013;small cell lung cancer (NSCLC) cohorts of EV-202. J. Clin. Oncol. 2024;42:8585. doi: 10.1200/JCO.2024.42.16_suppl.8585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2024.42.16_suppl.8585</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigby M., Bennett G., Chen L., Mudd G.E., Harrison H., Beswick P.J., Van Rietschoten K., Watcham S.M., Scott H.S., Brown A.N., et al. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors. Mol. Cancer Ther. 2022;21:1747&#x2013;1756. doi: 10.1158/1535-7163.MCT-21-0875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-21-0875</ArticleId><ArticleId IdType="pmc">PMC9940631</ArticleId><ArticleId IdType="pubmed">36112771</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura N., Fujiwara Y., Hashimoto T., Shiraishi H., Kitano S., Shimizu T., Kuwano K., Yamamoto N., Motoi N. Correlation between the expression of folate receptor alpha (FR&#x3b1;) and clinicopathological features in patients with lung adenocarcinoma. Lung Cancer. 2020;145:152&#x2013;157. doi: 10.1016/j.lungcan.2020.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2020.05.002</ArticleId><ArticleId IdType="pubmed">32450493</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Shannessy D.J., Somers E.B., Smale R., Fu Y.S. Expression of folate receptor-&#x3b1; (FRA) in gynecologic malignancies and its relationship to the tumor type. Int. J. Gynecol. Pathol. 2013;32:258&#x2013;268. doi: 10.1097/PGP.0b013e3182774562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PGP.0b013e3182774562</ArticleId><ArticleId IdType="pubmed">23518909</ArticleId></ArticleIdList></Reference><Reference><Citation>Necela B.M., Crozier J.A., Andorfer C.A., Lewis-Tuffin L., Kachergus J.M., Geiger X.J., Kalari K.R., Serie D.J., Sun Z., Moreno-Aspitia A., et al. Folate receptor-&#x3b1; (FOLR1) expression and function in triple negative tumors. PLoS ONE. 2015;10:e0122209. doi: 10.1371/journal.pone.0122209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0122209</ArticleId><ArticleId IdType="pmc">PMC4376802</ArticleId><ArticleId IdType="pubmed">25816016</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazaki S., Kojima Y., Yoshida H., Takamizawa S., Kitadai R., Nishikawa T., Shimoi T., Sudo K., Saito A., Okuma H.S., et al. High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer. J. Gynecol. Oncol. 2022;33:e82. doi: 10.3802/jgo.2022.33.e82.</Citation><ArticleIdList><ArticleId IdType="doi">10.3802/jgo.2022.33.e82</ArticleId><ArticleId IdType="pmc">PMC9634091</ArticleId><ArticleId IdType="pubmed">36245230</ArticleId></ArticleIdList></Reference><Reference><Citation>OShannessy D.J., Yu G., Smale R., Fu Y.S., Singhal S., Thiel R.P., Somers E.B., Vachani A. Folate receptor alpha expression in lung cancer: Diagnostic and prognostic significance. Oncotarget. 2012;3:414&#x2013;425. doi: 10.18632/oncotarget.519.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.519</ArticleId><ArticleId IdType="pmc">PMC3380576</ArticleId><ArticleId IdType="pubmed">22547449</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu T., Fujiwara Y., Yonemori K., Koyama T., Sato J., Tamura K., Shimomura A., Ikezawa H., Nomoto M., Furuuchi K., et al. First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-&#x3b1;-Positive Advanced Solid Tumors. Clin. Cancer Res. 2021;27:3905&#x2013;3915. doi: 10.1158/1078-0432.CCR-20-4740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-20-4740</ArticleId><ArticleId IdType="pubmed">33926914</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttenlocher A., Horwitz A.R. Integrins in cell migration. Cold Spring Harb. Perspect. Biol. 2011;3:a005074. doi: 10.1101/cshperspect.a005074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a005074</ArticleId><ArticleId IdType="pmc">PMC3181029</ArticleId><ArticleId IdType="pubmed">21885598</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper J., Giancotti F.G. Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell. 2019;35:347&#x2013;367. doi: 10.1016/j.ccell.2019.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2019.01.007</ArticleId><ArticleId IdType="pmc">PMC6684107</ArticleId><ArticleId IdType="pubmed">30889378</ArticleId></ArticleIdList></Reference><Reference><Citation>Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577&#x2013;584. doi: 10.1038/nature02006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02006</ArticleId><ArticleId IdType="pubmed">14534577</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung J., Kim T.H. Integrin-dependent translational control: Implication in cancer progression. Microsc. Res. Tech. 2008;71:380&#x2013;386. doi: 10.1002/jemt.20566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jemt.20566</ArticleId><ArticleId IdType="pubmed">18300291</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhurst R.J., Hata A. Targeting the TGF&#x3b2; signalling pathway in disease. Nat. Rev. Drug Discov. 2012;11:790&#x2013;811. doi: 10.1038/nrd3810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3810</ArticleId><ArticleId IdType="pmc">PMC3520610</ArticleId><ArticleId IdType="pubmed">23000686</ArticleId></ArticleIdList></Reference><Reference><Citation>Prud'homme G.J. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab. Invest. 2007;87:1077&#x2013;1091. doi: 10.1038/labinvest.3700669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.3700669</ArticleId><ArticleId IdType="pubmed">17724448</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni Y., Soliman A., Joehlin-Price A., Rose P.G., Vlad A., Edwards R.P., Mahdi H. High TGF-&#x3b2; signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition. NPJ Precis. Oncol. 2021;5:101. doi: 10.1038/s41698-021-00242-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41698-021-00242-8</ArticleId><ArticleId IdType="pmc">PMC8683510</ArticleId><ArticleId IdType="pubmed">34921236</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahmani A., Delisle J.S. TGF-&#x3b2; in T Cell Biology: Implications for Cancer Immunotherapy. Cancers. 2018;10:194. doi: 10.3390/cancers10060194.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers10060194</ArticleId><ArticleId IdType="pmc">PMC6025055</ArticleId><ArticleId IdType="pubmed">29891791</ArticleId></ArticleIdList></Reference><Reference><Citation>Elayadi A.N., Samli K.N., Prudkin L., Liu Y.H., Bian A., Xie X.J., Wistuba I.I., Roth J.A., McGuire M.J., Brown K.C. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 2007;67:5889&#x2013;5895. doi: 10.1158/0008-5472.CAN-07-0245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-07-0245</ArticleId><ArticleId IdType="pubmed">17575158</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z.Y., Xu K.S., Wang J.S., Yang G.Y., Wang W., Wang J.Y., Niu W.B., Liu E.Y., Mi Y.T., Niu J. Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma. Clin. Oncol. (R. Coll. Radiol.) 2008;20:61&#x2013;66. doi: 10.1016/j.clon.2007.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clon.2007.09.008</ArticleId><ArticleId IdType="pubmed">17981018</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengs S., Becker E., Busenhart P., Spalinger M.R., Raselli T., Kasper S., Lang S., Atrott K., Mamie C., Vavricka S.R., et al. &#x3b2; 6-integrin serves as a novel serum tumor marker for colorectal carcinoma. Int. J. Cancer. 2019;145:678&#x2013;685. doi: 10.1002/ijc.32137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.32137</ArticleId><ArticleId IdType="pubmed">30653264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazelbag S., Kenter G.G., Gorter A., Dreef E.J., Koopman L.A., Violette S.M., Weinreb P.H., Fleuren G.J. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J. Pathol. 2007;212:316&#x2013;324. doi: 10.1002/path.2168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2168</ArticleId><ArticleId IdType="pubmed">17503414</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., He Z., Jiang Z., Liu Z., Zhuang X. Acidity-induced ITGB6 promote migration and invasion of lung cancer cells by epithelial-mesenchymal transition and focal adhesion. Exp. Cell Res. 2024;436:113962. doi: 10.1016/j.yexcr.2024.113962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2024.113962</ArticleId><ArticleId IdType="pubmed">38316250</ArticleId></ArticleIdList></Reference><Reference><Citation>Breuss J.M., Gallo J., DeLisser H.M., Klimanskaya I.V., Folkesson H.G., Pittet J.F., Nishimura S.L., Aldape K., Landers D.V., Carpenter W. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. Pt 6J. Cell Sci. 1995;108:2241&#x2013;2251. doi: 10.1242/jcs.108.6.2241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.108.6.2241</ArticleId><ArticleId IdType="pubmed">7673344</ArticleId></ArticleIdList></Reference><Reference><Citation>Trang T., Mazahreh R., Gosink J., Ulrich M., Olson D., Ubben A., Allred S., Huang L., Hensley K., Treuting P. Abstract 1522: SGN-B6A induces immunogenic cell death as an additional mechanism of action. Cancer Res. 2023;83:1522. doi: 10.1158/1538-7445.AM2023-1522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2023-1522</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters S., Hollebecque A., Sehgal K., Lopez J., Calvo E., Dowlati A., Bockorny B., Perez C., Sanborn R. Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001) J. Clin. Oncol. 2024;42:8521. doi: 10.1200/JCO.2024.42.16_suppl.8521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2024.42.16_suppl.8521</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang J.W., Cho Y., Bae G.U., Kim S.N., Kim Y.K. Protein arginine methyltransferases: Promising targets for cancer therapy. Exp. Mol. Med. 2021;53:788&#x2013;808. doi: 10.1038/s12276-021-00613-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-021-00613-y</ArticleId><ArticleId IdType="pmc">PMC8178397</ArticleId><ArticleId IdType="pubmed">34006904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H., Ronai Z.A. PRMT5 function and targeting in cancer. Cell Stress. 2020;4:199&#x2013;215. doi: 10.15698/cst2020.08.228.</Citation><ArticleIdList><ArticleId IdType="doi">10.15698/cst2020.08.228</ArticleId><ArticleId IdType="pmc">PMC7380451</ArticleId><ArticleId IdType="pubmed">32743345</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing P., Zhao N., Ye M., Zhang Y., Zhang Z., Sun J., Wang Z., Zhang J., Gu Z. Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling. Cancer Lett. 2018;427:38&#x2013;48. doi: 10.1016/j.canlet.2018.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2018.04.019</ArticleId><ArticleId IdType="pubmed">29679612</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M., Hong S., Li W., Wang P., You J., Zhang X., Tang F., Zhang C. MiR-99a regulates ROS-mediated invasion and migration of lung adenocarcinoma cells by targeting NOX4. Oncol. Rep. 2016;35:2755&#x2013;2766. doi: 10.3892/or.2016.4672.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2016.4672</ArticleId><ArticleId IdType="pubmed">26986073</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal S., Vishwanath S.N., Erdjument-Bromage H., Tempst P., Sif S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol. Cell Biol. 2004;24:9630&#x2013;9645. doi: 10.1128/MCB.24.21.9630-9645.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.24.21.9630-9645.2004</ArticleId><ArticleId IdType="pmc">PMC522266</ArticleId><ArticleId IdType="pubmed">15485929</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu T., Lv X., Kong Q., Yuan C. A novel SHARPIN-PRMT5-H3R2me1 axis is essential for lung cancer cell invasion. Oncotarget. 2017;8:54809&#x2013;54820. doi: 10.18632/oncotarget.18957.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.18957</ArticleId><ArticleId IdType="pmc">PMC5589623</ArticleId><ArticleId IdType="pubmed">28903384</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Chen Z.H., Savarese T.M. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. Cancer Genet. Cytogenet. 1996;86:22&#x2013;28. doi: 10.1016/0165-4608(95)00157-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-4608(95)00157-3</ArticleId><ArticleId IdType="pubmed">8616780</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjon K., Cameron M.J., Quang P., Clasquin M.F., Mandley E., Kunii K., McVay M., Choe S., Kernytsky A., Gross S., et al. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis. Cell Rep. 2016;15:574&#x2013;587. doi: 10.1016/j.celrep.2016.03.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.03.043</ArticleId><ArticleId IdType="pubmed">27068473</ArticleId></ArticleIdList></Reference><Reference><Citation>Stopa N., Krebs J.E., Shechter D. The PRMT5 arginine methyltransferase: Many roles in development, cancer and beyond. Cell Mol. Life Sci. 2015;72:2041&#x2013;2059. doi: 10.1007/s00018-015-1847-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-015-1847-9</ArticleId><ArticleId IdType="pmc">PMC4430368</ArticleId><ArticleId IdType="pubmed">25662273</ArticleId></ArticleIdList></Reference><Reference><Citation>Shilo K., Wu X., Sharma S., Welliver M., Duan W., Villalona-Calero M., Fukuoka J., Sif S., Baiocchi R., Hitchcock C.L., et al. Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors. Diagn. Pathol. 2013;8:201. doi: 10.1186/1746-1596-8-201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1746-1596-8-201</ArticleId><ArticleId IdType="pmc">PMC3933389</ArticleId><ArticleId IdType="pubmed">24326178</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal P., Vaites L.P., Kim J.K., Mellert H., Gurung B., Nakagawa H., Herlyn M., Hua X., Rustgi A.K., McMahon S.B., et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell. 2010;18:329&#x2013;340. doi: 10.1016/j.ccr.2010.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2010.08.012</ArticleId><ArticleId IdType="pmc">PMC2957477</ArticleId><ArticleId IdType="pubmed">20951943</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon J.Y., Lee J.S., Park E.R., Shen Y.N., Kim M.Y., Shin H.J., Joo H.Y., Cho E.H., Moon S.M., Shin U.S., et al. Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells. Oncol. Rep. 2018;40:536&#x2013;544. doi: 10.3892/or.2018.6402.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2018.6402</ArticleId><ArticleId IdType="pubmed">29749478</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Wang Z., Zhang J., Ling R. Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer. Tumour Biol. 2017;39:1010428317695917. doi: 10.1177/1010428317695917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1010428317695917</ArticleId><ArticleId IdType="pubmed">28381188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim R., Matsubara D., Osman W., Morikawa T., Goto A., Morita S., Ishikawa S., Aburatani H., Takai D., Nakajima J., et al. Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition. Hum. Pathol. 2014;45:1397&#x2013;1405. doi: 10.1016/j.humpath.2014.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humpath.2014.02.013</ArticleId><ArticleId IdType="pubmed">24775604</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X., Li R., Zhang W., Yang X., Wheeler C.G., Friedman G.K., Province P., Ding Q., You Z., Fathallah-Shaykh H.M., et al. Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. J. Neuroon. 2014;118:61&#x2013;72. doi: 10.1007/s11060-014-1419-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11060-014-1419-0</ArticleId><ArticleId IdType="pmc">PMC4076054</ArticleId><ArticleId IdType="pubmed">24664369</ArticleId></ArticleIdList></Reference><Reference><Citation>Gy&#x151;rffy B., Surowiak P., Budczies J., L&#xe1;nczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS ONE. 2013;8:e82241. doi: 10.1371/journal.pone.0082241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0082241</ArticleId><ArticleId IdType="pmc">PMC3867325</ArticleId><ArticleId IdType="pubmed">24367507</ArticleId></ArticleIdList></Reference><Reference><Citation>Brehmer D., Beke L., Wu T., Millar H.J., Moy C., Sun W., Mannens G., Pande V., Boeckx A., van Heerde E., et al. Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity. Mol. Cancer Ther. 2021;20:2317&#x2013;2328. doi: 10.1158/1535-7163.MCT-21-0367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-21-0367</ArticleId><ArticleId IdType="pmc">PMC9398174</ArticleId><ArticleId IdType="pubmed">34583982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahnert J., Perez C., Wong K., Maitland M., Tsai F., Berlin J., Liao K., Wang I., Markovtsova L. PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study. J. Clin. Oncol. 2021;39:3019. doi: 10.1200/JCO.2021.39.15_suppl.3019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2021.39.15_suppl.3019</ArticleId></ArticleIdList></Reference><Reference><Citation>Siu L., Rasco D., Vinay S., Romano P., Menis J., Opdam F., Heinhuis K., Egger J., Gorman S. METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumors. Ann. Oncol. 2019;30:v159&#x2013;v193. doi: 10.1093/annonc/mdz244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdz244</ArticleId></ArticleIdList></Reference><Reference><Citation>Engstrom L.D., Aranda R., Waters L., Moya K., Bowcut V., Vegar L., Trinh D., Hebbert A., Smith C.R., Kulyk S., et al. MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer. Cancer Discov. 2023;13:2412&#x2013;2431. doi: 10.1158/2159-8290.CD-23-0669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-23-0669</ArticleId><ArticleId IdType="pmc">PMC10618744</ArticleId><ArticleId IdType="pubmed">37552839</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottrell K.M., Briggs K.J., Whittington D.A., Jahic H., Ali J.A., Davis C.B., Gong S., Gotur D., Gu L., McCarren P., et al. Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers. J. Med. Chem. 2024;67:6064&#x2013;6080. doi: 10.1021/acs.jmedchem.4c00133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.4c00133</ArticleId><ArticleId IdType="pmc">PMC11056935</ArticleId><ArticleId IdType="pubmed">38595098</ArticleId></ArticleIdList></Reference><Reference><Citation>Villalona-Calero M., Patnaik A., Maki R., O&#x2019;Neil B., Abbruzzese J., Dagogo-Jack I., Devarakonda S., Wahlroos S., Lin C. Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. J. Clin. Oncol. 2022;40:TPS3167. doi: 10.1200/JCO.2022.40.16_suppl.TPS3167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2022.40.16_suppl.TPS3167</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., de Camargo Correia G.S., Wang J., Manochakian R., Zhao Y., Lou Y. Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer. Cancers. 2023;15:2899. doi: 10.3390/cancers15112899.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15112899</ArticleId><ArticleId IdType="pmc">PMC10251928</ArticleId><ArticleId IdType="pubmed">37296863</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo A., Cardona A.F., Caglevic C., Manca P., Ruiz-Pati&#xf1;o A., Arrieta O., Rolfo C. Overcoming TKI resistance in fusion-driven NSCLC: New generation inhibitors and rationale for combination strategies. Transl. Lung Cancer Res. 2020;9:2581&#x2013;2598. doi: 10.21037/tlcr-2019-cnsclc-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tlcr-2019-cnsclc-06</ArticleId><ArticleId IdType="pmc">PMC7815353</ArticleId><ArticleId IdType="pubmed">33489820</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>